Oragenics explores potential acquisition of additional assets in CNS space

Oragenics (OGEN) announced that it is exploring discussions with third parties regarding the potential acquisition of additional assets in the central nervous system space, with a specific focus on brain health and brain recovery indications that demonstrate strategic synergies with the Company’s lead candidate ONP-002 and its proprietary intranasal drug delivery platform. No definitive agreements have been reached, and there can be no assurance that any transaction will be completed on terms acceptable to the Company, or at all. The Company will disclose any material transaction in accordance with applicable securities laws and regulations.